Applications

Digital twins across oncology development.

Evinexus digital twins support trial design, external and hybrid control arms, and evidence generation across oncology development.

Contact us See the evidence

Across trial phases

Where digital twins add value across development.

Phase I / II

  • Trial-design simulation
  • Go/no-go and futility decision support
  • Predictive enrichment of biomarker-defined subgroups

Phase II / III

  • Potentially smaller control groups while preserving operating characteristics
  • Greater precision in key subgroups
  • Prognostic covariate adjustment for efficiency

Single-arm / rare

  • External and hybrid control strategies
  • Potentially reduced control allocation and enrollment burden
  • Comparator evidence for rare and hard-to-enroll populations

Cross-cutting

  • Predictions specified before outcomes are unblinded
  • Masked, pre-specified analyses designed to reduce bias
  • Potential time and cost savings across development

Illustrative example — cohort filters

Example cohort questions

These are prepared example questions, not a free-form query.

Cancer type

Drug class

Age (years)active
torange 21–85 · 4,820 of 4,820
Sexactive

Matched cohort

228of 4,820 match (4.7%)

Applied — Sex, age, and prior-therapy filters applied.

Sex: FemaleAge (years): ≥ 65Prior systemic therapy: Yes

Attrition funnel

Starting pool4,820
Sex: Female2,464
Age (years): ≥ 65474
Prior systemic therapy: Yes228

228 of 4,820 matched (4.7%)

Pool cohorts for analysis

Illustrative
Sample cohort filtering. Select criteria to see the matched population and funnel update.

Evidence generation

Comparator strategies for different study designs.

  • Primary application

    Regulatory-grade external control arms

    Use a protocol-aligned external cohort when a concurrent control is infeasible or impractical.

  • Hybrid control arms

    Supplement a smaller randomized control with prespecified external evidence.

  • Natural history studies

    Describe disease course and outcomes for single-arm or rare-disease studies.

Illustrative example — control strategies

Standard control
External control
Hybrid control
0.800.901.001.101.20

Relative effect (vs. standard control) — illustrative example, not a validated result.

Illustrative
Control-strategy comparison.

Trial design

  • Feasibility and eligibility

    Assess population size, variables, endpoints, and expected events.

  • Patient and biomarker strategy

    Examine enrichment criteria and clinically relevant subgroups.

  • Development scenarios

    Compare assumptions relevant to regimen, timing, or program decisions.

Illustrative example — eligibility funnel

Screened population3,400
Meets eligibility criteria1,900
Confirmed eligible860
Matched cohort340

Sample population narrowing to a matched, protocol-eligible cohort.

Illustrative
Feasibility and eligibility.

Assumption · Dosing interval

StandardExtended
Illustrative
Scenario comparison.

Tell us more about your study.

Share the indication, population, endpoint, and intended use so Evinexus can assess the appropriate application.

Contact us